# Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma

> **NCT00074191** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 1 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** cytarabine
- **DRUG:** dexamethasone
- **DRUG:** lomustine
- **DRUG:** methotrexate
- **DRUG:** procarbazine hydrochloride

## Key facts

- **NCT ID:** NCT00074191
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2000-10
- **Final completion:** 2000-10
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074191, "Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00074191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*